BEIJING — A specialized electronic comb that stimulates follicles with electric pulses while delivering therapeutic molecules restored nearly all lost hair in mice within one month, according to a study published in the journal Nature Communications.
The experimental device, developed by researchers at Beihang University in Beijing, was designed to treat androgenetic alopecia, commonly known as pattern baldness. While traditional medications often produce inconsistent results and require months of continuous use, the comb achieved a 97.85 percent regrowth rate in animal trials by combining physical stimulation with targeted drug delivery, ScienceAlert reported.
A dual approach to regrowing hair
Dubbed “Detangle” — a name its creators said was inspired by the Disney movie “Tangled” — the handheld apparatus closely resembles a traditional grooming tool but functions as a bioelectronic platform, Yahoo reported. Its teeth feature alternating lengths that serve as height-differentiated electrodes.
According to the study, the staggered arrangement creates an electric field 2.63 times stronger than rows of evenly aligned teeth. This design enables the pulsed electric fields to penetrate up to nine times deeper into hair follicle regions than conventional topical applications.
The system operates through a two-part mechanism. First, electrical pulses directly stimulate dormant hair follicles. Second, the energy triggers electroporation, a process that temporarily increases the permeability of cell membranes. This enables small compartments embedded in the shorter teeth to drive therapeutic compounds deep into follicular cells, boosting cellular uptake by more than three times, the researchers reported.
For the animal trials, scientists loaded the device with two experimental genetic compounds: a VEGFA plasmid, which encourages blood vessel formation around hair follicles, and SRD5A2 siRNA, a molecule that suppresses the production of dihydrotestosterone, a hormone responsible for shrinking follicles.
Surpassing standard therapies in lab tests
Researchers evaluated the technology on male mice with hormone-induced hair loss over a 28-day period, testing various interventions on shaved patches of their backs. The results showed that untreated mice regrew only about 1 percent of their hair during the four-week trial, according to ScienceAlert.
Electrostimulation alone spurred roughly 40 percent regrowth. That outperformed the untreated group but lagged behind standard pharmaceutical therapies. In comparison, mice treated with finasteride saw about 50 percent regrowth, while those receiving topical minoxidil reached approximately 70 percent, the researchers found.
The comb’s performance increased significantly when paired with genetic therapies. Electrostimulation combined with the hormone-blocking siRNA achieved about 85 percent regrowth, while pairing the comb with the vessel-stimulating plasmid produced around 90 percent recovery. When researchers administered the complete treatment — delivering both genetic agents alongside electrical stimulation — hair regrowth reached nearly 100 percent.
The hurdle before human trials
Androgenetic alopecia is estimated to impact between 1 billion and 1.5 billion people globally, affecting up to 80 percent of men during their lifetimes, The Independent reported. Despite its prevalence, standard treatments remain limited. Topical minoxidil can take up to a year to show measurable effects, can cause scalp irritation and headaches, and must be applied continuously to maintain results. Finasteride carries risks of depression and sexual dysfunction, while surgical hair transplants remain invasive, painful, and costly.
Although the comb significantly outperformed topical minoxidil in the laboratory, the researchers emphasized that the technology remains experimental. While mouse models serve as a standard testing ground in biomedical research, there is no proof yet that the device will produce identical outcomes on human scalps.
Scientists from Beihang University noted that extensive safety evaluations and further laboratory testing are necessary before researchers can begin clinical trials in humans to evaluate whether the electronic comb is both safe and effective for widespread medical use.



